Hims & Hers Health And Novo Nordisk: A Corporate Remarriage That May Work Out Profitably (NYSE:HIMS)

This article seeks to analyze whether Hims and HERS Health, Inc. (HIM) stock is overpriced due to the short-term euphoria resulting from its remarriage with Novo Nordisk and short-covering, or undervalued by Mr. Market because of the perceived instability ofI run my own boutique law firm, focusing on investment transactions and disputes. Trained at top U.S. law schools and leading Wall Street law firms, I write here primarily to sharpen my own thinking and to engage with my followers. I endeavor to respond ...